Phase I Study of Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Trial Profile

Phase I Study of Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2018

At a glance

  • Drugs Interleukin-15 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Jan 2018 Planned initiation date changed from 5 Feb 2018 to 6 Feb 2018.
    • 31 Jan 2018 Planned initiation date changed from 1 Feb 2018 to 5 Feb 2018.
    • 26 Jan 2018 Planned initiation date changed from 31 Jan 2018 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top